[1] |
Iavarone M, Colombo M. HBV infection and hepatocellular carcinoma. Clin Liver Dis, 2013; 17, 375−97. doi: 10.1016/j.cld.2013.05.002 |
[2] |
Li Y, Zhang Z, Shi J, et al. Risk factors for naturally-occurring early-onset hepatocellular carcinoma in patients with HBV-associated liver cirrhosis in China. Int J Clin Exp Med, 2015; 8, 1205−12. |
[3] |
Zhu B, Liu J, Fu Y, et al. Spatio-temporal epidemiology of viral hepatitis in china (2003-2015): implications for prevention and control policies. Int J Environ Res Public Health, 2018; 15. |
[4] |
Liang X, Bi S, Yang W, et al. Epidemiological serosurvey of hepatitis B in China-declining HBV prevalence due to hepatitis B vaccination. Vaccine, 2009; 27, 6550−7. doi: 10.1016/j.vaccine.2009.08.048 |
[5] |
Zhang W, Ji Z, Fu T, et al. Meta analysis on HBsAg positive rate among general populations age d 1–59 years, 2007–2016, China. Chin J Epidemio, 2017; 38, 1278−84. |
[6] |
Zhang G, Miao N, Zheng H, et al. Incidence by age and region of hepatitis B reported in China from 2005 to 2016. Chin J Vaccine Immu, 2018; 24, 121−6. |
[7] |
Zhang Y, Zhang H, Elizabeth A, et al. Epidemiology of hepatitis B and associated liver diseases in China. Chin Med J, 2012; 27, 243−8. |
[8] |
Schweitzer A, Horn J, Mikolajczyk RT, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet, 2015; 386, 1546−55. doi: 10.1016/S0140-6736(15)61412-X |
[9] |
Zhang S, Wang F, Zhang Z. Current advances in the elimination of hepatitis B in China by 2030. Front Med, 2017; 11, 490−501. doi: 10.1007/s11684-017-0598-4 |
[10] |
Wang H, Men P, Xiao Y, et al. Hepatitis B infection in the general population of China: a systematic review and meta-analysis. BMC Infect Dis, 2019; 19, 811. doi: 10.1186/s12879-019-4428-y |
[11] |
Liu J, Liang W, Jing W, et al. Countdown to 2030: eliminating hepatitis B disease, China. B World Health Organ, 2019; 97, 230−8. doi: 10.2471/BLT.18.219469 |
[12] |
Kang L, Zhang J, Zhang Z. Analysis of epidemiological characteristics of hepatitis B and prevention strategy in Wuwei, Gansu province. Bull Dis Contr Pre, 2016; 31, 30−2. |
[13] |
Ji Z, Wang T, Shao Z, et al. A population-based study examining hepatitis B virus infection and immunization rates in Northwest China. PLoS One, 2014; 9, e97474. doi: 10.1371/journal.pone.0097474 |
[14] |
Zheng H, Wang FZ, Zhang GM, et al. The epidemiological characteristics of HBV susceptibility in 1–29 years old young people in China in 2006 and 2014: based on the national sero-survey data analysis. Chin J Epidemiol, 2017; 51, 581−6. |
[15] |
Fan Li, Qixia Wang, Lei Zhang, et al. The risk factors of transmission after the implementation of the routine immunization among children exposed to HBV infected mothers in a developing area in northwest China. Vaccine, 2012; 30, 7118−22. doi: 10.1016/j.vaccine.2012.09.031 |
[16] |
Guo M, Luo WW, Zhang DZ. Optimal cessation period of anti-HBV therapy to block mother-to-child transmission. China J Hepatol, 2019; 27, 92−6. |
[17] |
Yan Y, Zhang W, Su H, et al. Research progress and challenges for hepatitis B prevention and treatment in China. Trop Med Int Health, 2019; 19, 916−21. |
[18] |
Nayagam S, Shimakawa Y. Mother to child transmission of hepatitis B: What more needs to be done to eliminate it around the world? J Viral Hepatitis, 2020; 27, 342−9. doi: 10.1111/jvh.13231 |
[19] |
Tavakolpour S, Darvishi M, Mirsafaei HS, et al. Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B infection during pregnancy: a systematic review. Infect Dis (Lond), 2018; 50, 95−106. doi: 10.1080/23744235.2017.1384957 |
[20] |
Zhang W, Ji Z, Fu T, et al. Meta analysis on HBsAg·positive rate among general populations aged 1-59 years, 2007–2016, China. Chin J Epidemiol, 2017; 38, 1278−84. |
[21] |
Chu CM. Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol, 2000; 15, Suppl: E25–E30. |
[22] |
Idilman R. The summarized of EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. Turk J Gastroenterol, 2017; 28, 412−6. doi: 10.5152/tjg.2017.20817 |
[23] |
Hu P, Ren H. Interpretations of EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. China J Hepatol, 2017; 25, 415−8. |
[24] |
Hu P, Shang J, Zhang W, et al. HBsAg loss with peg-interferon alfa-2a in hepatitis B patients with partial response to nucleos(t)ide analog: new switch study. J Clin Transl Hepatol, 2018; 6, 25−34. |
[25] |
Idilman R. Management of special patient groups with hepatitis B virus infection: The EASL 2017 Clinical Practice Guidelines. Turk J Gastroenterol, 2017; 28, 518−21. |